Skip to content

Extended vs. Intermittent Meropenem Infusion in Sepsis Patients in the ICU

"The Impact of Meropenem Strategy on Treatment Efficacy in Sepsis and Septic Shock : Extended vs. Intermittent Dosing in the ICU"

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07398703
Enrollment
90
Registered
2026-02-10
Start date
2027-10-01
Completion date
2028-04-01
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Septic Shock

Keywords

Extended, Intermittent, infusion, Sepsis, Septic shock, Meropenem

Brief summary

This observational study compares extended versus intermittent beta-lactam infusion in sepsis patients, assessing survival, clinical cure rates, and practical ICU challenges. The findings will guide optimal antibiotic protocols, potentially improving sepsis outcomes through precision dosing strategies.

Detailed description

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock should be considered a subset of sepsis in which underlying circulatory, cellular, and metabolic abnormalities significantly increase mortality risk compared to sepsis alone. Beta-lactam antibiotics exhibit broad-spectrum activity against most Gram-positive and Gram-negative bacteria, making them a key component of sepsis treatment. Their bactericidal effects are time-dependent, meaning efficacy depends on maintaining free drug concentrations above the minimum inhibitory concentration of the target pathogen for an optimal duration. In clinical practice, beta-lactams are typically administered via intermittent infusion. However, critically ill patients often experience altered pharmacokinetics due to changes in renal clearance, protein binding, fluid balance, and volume distribution. This variability can lead to unpredictable drug concentrations, increasing the risk of subtherapeutic antibiotic exposure. Existing studies suggest that continuous infusion may enhance beta-lactam efficacy by maintaining drug concentrations above the minimum inhibitory concentration for longer periods, optimizing pharmacokinetic and pharmacodynamic targets. Some meta-analyses and small randomized controlled trials report reduced mortality and improved clinical cure rates with continuous infusion, while others show no significant difference. However, differences in dosing regimens, patient populations, and pharmacokinetic variability in critically ill patients make it difficult to draw firm conclusions.

Interventions

DRUGExtended beta-lactam antibiotics

Group A will be receiving extended infusion of beta-lactam antibiotic over 4 hours.

DRUGIntermittent Beta-lactam antibiotics

Group B will be receiving intermittent infusion of beta-lactam antibiotic over 30 minutes.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Aged: 18 - 65 * Patients admitted to critical care unit diagnosed with pneumonia with two of the following: 1. Temperature: over 38 degree celsius 2. Heart rate: over 100 beats per minute 3. Respiratory rate: over 20 breaths per minute 4. leucocyte count over than 12000 or less than 4000 microlitres or over 10% immature forms or bands * Patients with positive sputum

Exclusion criteria

* Hypersensitivity to Beta-lactams * Pregnancy * Very low probability of survival using APAACHE II score \> 34 points. * Immunodeficency or taking immunosuppressive medications * Acute or chronic renal failure with creatinine clearance less than 30 ml/min according to Cockcroft-Gault formula.

Design outcomes

Primary

MeasureTime frame
All-cause mortality at 28 days from the date of randomization.Baseline and 28 days

Secondary

MeasureTime frameDescription
Clinical cureBaseline and 16 daysdefined as completing the full course of beta-lactam therapy within 14 days without requiring additional antibiotics for the same infection within 48 hours after treatment cessation.

Contacts

CONTACTMostafa Y.S. Sayed, MBBS
mostafa.yousef43@gmail.com+201015479784

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026